- Home
- BBW vs ALT Comparison
BBW vs ALT Comparison
Compare BBW & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBW
- ALT
- Stock Information
- Founded
- BBW 1997
- ALT 1997
- Country
- BBW United States
- ALT United States
- Employees
- BBW N/A
- ALT N/A
- Industry
- BBW Recreational Games/Products/Toys
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- BBW Consumer Discretionary
- ALT Health Care
- Exchange
- BBW Nasdaq
- ALT Nasdaq
- Market Cap
- BBW 590.7M
- ALT 472.3M
- IPO Year
- BBW 2004
- ALT N/A
- Fundamental
- Price
- BBW $39.54
- ALT $6.64
- Analyst Decision
- BBW Strong Buy
- ALT Strong Buy
- Analyst Count
- BBW 3
- ALT 7
- Target Price
- BBW $54.33
- ALT $20.83
- AVG Volume (30 Days)
- BBW 291.5K
- ALT 2.1M
- Earning Date
- BBW 03-13-2025
- ALT 03-26-2025
- Dividend Yield
- BBW 2.08%
- ALT N/A
- EPS Growth
- BBW 8.16
- ALT N/A
- EPS
- BBW 3.79
- ALT N/A
- Revenue
- BBW $495,235,000.00
- ALT $52,000.00
- Revenue This Year
- BBW $2.53
- ALT N/A
- Revenue Next Year
- BBW $2.59
- ALT N/A
- P/E Ratio
- BBW $10.09
- ALT N/A
- Revenue Growth
- BBW 2.76
- ALT N/A
- 52 Week Low
- BBW $21.60
- ALT $5.28
- 52 Week High
- BBW $48.23
- ALT $14.84
- Technical
- Relative Strength Index (RSI)
- BBW 41.12
- ALT 40.91
- Support Level
- BBW $41.48
- ALT $6.15
- Resistance Level
- BBW $44.79
- ALT $7.18
- Average True Range (ATR)
- BBW 1.61
- ALT 0.33
- MACD
- BBW -0.07
- ALT 0.02
- Stochastic Oscillator
- BBW 22.05
- ALT 38.82
About BBW Build-A-Bear Workshop Inc.
Build-A-Bear Workshop Inc is a U.S.-based specialty retailer of customized stuffed animals and related products. The company operates through three segments. Its Direct-to-consumer segment with key revenue, includes the operating activities of corporately-managed locations and other retail delivery operations in the U.S., Canada, China, Denmark, Ireland, and the U.K., including the company's e-commerce sites and temporary stores. The international franchising segment includes the licensing activities of the company's franchise agreements with store locations in Europe, Asia, Australia, the Middle East, and Africa. The commercial segment includes the transactions with other businesses, mainly comprised of licensing the intellectual properties for third-party use and wholesale activities.
About ALT Altimmune Inc.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.